Background: The p53 tumor suppressor gene (also known as TP53) is one of the most frequently mutated genes in human cancer. Several studies have shown that p53 mutations are infrequent in prostate cancer and are associated with advanced disease. Purpose: We assessed the prognostic value of identifying abnormal p53 protein expression in the tumors of patients with locally advanced prostate cancer who were treated with either external-beam radiation therapy alone or total androgen blockade before and during the radiation therapy. Methods: The study population consisted of a subset of patients entered in Radiation Therapy Oncology Group protocol 8610 (''a phase III trial of Zoladex and flutamide used as cytoreductive agents in locally advanced carcinoma of the prostate treated with definitive radiotherapy''). Immunohistochemical detection of abnormal p53 protein in pretreatment specimens (i.e., needle biopsies or transurethral resections) was achieved by use of the monoclonal antip53 antibody DO7; specimens in which 20% or more of the tumor cell nuclei showed positive immunoreactivity were considered to have abnormal p53 protein expression. Associations between p53 protein expression status and the time to local progression, the incidence of distant metastases, progression-free survival, and overall survival were evaluated in univariate (logrank test) and multivariate (Cox proportional hazards model) analyses. Reported P values are two-sided. Results: One hundred twenty-nine (27%) of the 471 patients entered in the trial had sufficient tumor material for analysis. Abnormal p53 protein expression was detected in the tumors of 23 (18%) of these 129 patients. Statistically significant associations were found between the presence of abnormal p53 protein expression and increased incidence of distant metastases (P = .04), decreased progression-free survival (P = .03), and decreased overall survival (P = .02); no association was found between abnormal p53 protein expression and the time to local progression (P = .58). These results were independent of the Gleason score and clinical stage. A significant treatment interaction was detected with respect to the development of distant metastases: Among patients receiving both radiation therapy and hormone therapy, those with tumors exhibiting abnormal p53 protein expression experienced a reduced time to the development of distant metastases (P = .001); for patients treated with radiation therapy alone, the time to distant metastases was unrelated to p53 protein expression status (P = .91). Conclusions: Determination of p53 protein expression status yields signifi-
The p53 tumor suppressor gene (also known as TP53) is recognized to be one of the most frequently mutated genes in all human cancers. The p53 protein has been found to have a myriad of functions crucial to normal cell proliferation, apoptosis, and DNA repair, among others (1, 2) . Since the first description of p53 mutations in prostate cancer cell lines (3) , numerous studies (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) have been published concerning p53 gene mutation and prostate cancer. These studies have generally shown a low rate of mutation and an association with advanced disease. Many analyses have used immunohistochemistry to evaluate p53 gene status. In tumors with p53 mutations, the mutant protein is not metabolized normally and accumulates in the nucleus, thus allowing its detection. However, positive immunohistochemical detection does not necessarily indicate the presence of a mutation, since the protein can accumulate for other reasons, such as abnormalities in other genes involved in p53 regulation and metabolism (18) . Finally, not all tumors with p53 mutations will have detectable protein; for example, some insertion or deletion mutations could result in a truncated protein not containing the antigenic site recognized by the specific antibody being used (20) .
Radiation Therapy Oncology Group (RTOG) protocol 8610 was a phase III, randomized, clinical trial that tested the benefits of 4 months of maximum androgen blockade as a cytoreductive treatment prior to (2 months) and during external-beam radiation therapy (RT) for locally advanced prostate cancer. The population studied in this trial consisted of a poor-prognosis group with large tumors (palpable surface area of 25 cm 2 or greater) and a high proportion of high-grade cancers [28% with a Gleason score (21) of [8] [9] [10] . At the time of initial analysis, the results of the trial showed a significant improvement in local control and progression-free survival for patients receiving hormone therapy (22) . The purpose of this study was to assess the prognostic value of identifying p53 abnormalities in these patients with locally advanced prostate cancer who were treated with RT with or without neoadjuvant total androgen blockade.
Materials and Methods

Study Population
For this retrospective study, a subset of the patients entered in RTOG 8610 who had sufficient pathologic material available was studied. RTOG 8610 (''a phase III trial of Zoladex and flutamide used as cytoreductive agents in locally advanced carcinoma of the prostate treated with definitive radiotherapy'') closed in 1991 with a total of 471 patients entered; 456 of the patients were assessable. Results from the trial demonstrated a significant reduction in local progression and a prolongation of progression-free survival for the patients receiving neoadjuvant hormonal therapy (22) . Diagnostic material (from needle biopsies or transurethral resections) was reviewed centrally for 461 (98%) of the 471 patients by the study pathologist (D. J. Grignon), and the tumors were graded according to the criteria of Gleason (21) . Tissue blocks were requested from participating institutions (>100) at the time of central pathology review for all cases that were reviewed. Pretreatment serum prostate-specific antigen (PSA) determinations were available for only 19 (15%) of the 129 patients considered in this study and could not be included in the multivariate regression analysis.
Immunohistochemistry
Tissue specimens, cut in 5-m-thick sections, were immunostained for the presence of p53 protein by use of a mouse monoclonal antibody directed against mutant and wild-type p53 (clone DO7; Novocastra, Burlingame, CA). This antibody was selected because we have extensive experience with it in our laboratory; and, in our hands, there is no substantial difference between its sensitivity and that of other commercially available antibodies (including antibody 1801) (20) . Immunostaining was performed using a method (the ABC method) that employs avidin-biotin complexes after microwave antigen retrieval (23) . Slides containing tumor sections were placed in a 10 mM citrate buffer solution (pH 6.0) and heated in a 750-W microwave oven set on ''high'' for three 5-minute cycles; the slides were then allowed to cool in the hot solution for 20 minutes at room temperature. Endogenous peroxidase activity was blocked with 3% H 2 O 2 , and nonspecific antibody binding was blocked with horse and bovine serum albumin. The primary antibody (DO7) was diluted 1:100 in antibody diluent (Ventana Medical Systems, Tucson, AZ) and incubated with the slides at room temperature for 20 minutes. Immune complexes were detected by use of the ABC method with 3-amino-9-ethylcarbazole as the chromogen. A colon carcinoma with a known p53 mutation served as a positive control specimen, and negative control specimens included a breast carcinoma known not to have a p53 mutation and sections stained without the primary antibody.
For inclusion in the study, the stained section had to contain identifiable carcinoma. Sections were evaluated without knowledge of patient outcome. Only nuclear immunoreactivity was considered to represent positive staining. Immunohistochemical staining was scored semiquantitatively as follows: 0 ‫ס‬ no detectable positive cells, 1 ‫ס‬ one detectable cell up to 1% of tumor cells positive, 2 ‫ס‬ more than 1%-19% tumor cells positive, 3 ‫ס‬ 20%-49% tumor cells positive, and 4 ‫ס‬ 50% or more tumor cells positive. For the statistical analysis, specimens with fewer than 20% positive nuclei were considered to have normal p53 expression, and specimens with 20% or more positive nuclei were considered to have abnormal expression. This cutoff point was selected for several reasons. First, in the only other study of prostate cancer to demonstrate a significant relationship between p53 protein expression and survival, this cutoff point was used (4) . Second, use of this same cutoff point in other organ systems has been found to provide the greatest prognostic power [e.g., see (24) ]. Finally, in our own laboratory, studies of breast and prostate cancer using the DO7 antibody have shown this level of p53 expression to correlate with the presence of a mutation in more than 90% of the cases (18, 20) .
Definition of End Points
The four end points used in the analysis were local progression, time to distant metastases, progression-free survival, and overall survival. With the exception of local progression, they were defined as in the initial treatment report (22) . For this study, local progression (regrowth) was defined as an increase in tumor size of more than 50% for cases where complete tumor regression did not occur, recurrence of a palpable nodule when there was complete regression, or a positive biopsy of the prostate after 2 or more years of follow-up. PSA failure (i.e., an increase in serum PSA value) was not included in the definition of local failure. Regional metastases were defined by clinical or radiologic evidence of disease in the pelvis at sites other than the prostate. Distant metastasis was defined as clinical or radiologic evidence of disease outside the pelvis. A failure in progression-free survival included failure in any of the above end points or death. Progression-free survival used PSA determinations as part of the criteria. Since the original treatment protocol was designed before PSA values were available, 14 patients with p53 results did not have PSA values and were thus excluded from the analyses of that end point. For all end points, time was measured from the date of random assignment to treatment to the first reported failure date or the last follow-up date if the patient did not fail. It should be noted that patients who died without local progression and/or distant metastases were counted as censored on the date of their death.
Statistical Analysis
The analysis was done with all data received at the RTOG headquarters and processed as of June 29, 1995 . This time period includes 15 additional months of follow-up from the initial treatment report (22) . The median follow-up for living patients for the entire study is 4.6 years (range, 0.87-7.23 years). If the analysis is restricted to patients with p53 data, the median follow-up is 5.0 years (range, 1.17-7.14 years).
The distributions of patient characteristics and treatment assignments for various patient subgroups were compared by the Pearson chi-squared test with the Yates correction factor. For the univariate analysis of all four end points, the comparisons were performed with the logrank test (25) . A significant treatment effect with hormones was found for local progression and progression-free survival in the original analysis (22) .
Several analyses were undertaken for each of the four end points using multivariate Cox proportional hazards models. The first set of analyses assessed possible differences in outcome between patients with or without a p53 determination. The second set of analyses evaluated the three possible cutoff points for p53 abnormality. The third set of analyses determined if there was a treatment interaction with p53 protein expression level (26) . Because of the small number of patients with abnormal p53 expression assigned to the RT-alone arm (n ‫ס‬ 12) and to the RT plus hormone-therapy arm (n ‫ס‬ 11), only large interaction effects could be detected as statistically significant. Each Cox model had treatment assignment, clinical tumor (T) stage (27) , and Gleason grade (21) as fixed covariates. The latter two factors were used as stratifying variables for randomization in the trial. All factors were considered as dichotomous variables and coded as follows: treatment (0 ‫ס‬ RT alone versus 1 ‫ס‬ RT plus hormone therapy); grouped Gleason sums (0 ‫ס‬ sums 2-7 versus 1 ‫ס‬ sums 8-10); clinical T stage (0 ‫ס‬ T2 versus 1 ‫ס‬ T3); p53 determination available for patient (0 ‫ס‬ no versus 1 ‫ס‬ yes); and p53 cut point (0 ‫ס‬ below considered normal versus 1 ‫ס‬ above considered normal). With each of the four end points, the models were derived with or without the covariate under test, and then the likelihood ratio test was used to evaluate its statistical significance at the .10 level. The fitted parameter associated with each variable from the model evaluating the prognostic value of p53 was used to estimate the relative risk (RR) ratio of failing when one of its subgroups was compared with the other and its 95% confidence interval (CI). A ratio of 1 indicates no difference between the two subgroups; the bigger the difference from 1, the greater the difference in the failure rates between the two subgroups. The treatment effect was modeled in such a way that a value less than 1 favored the addition of hormones. All statistical comparisons were made with two-tailed tests.
Progression-free survival and overall survival curves were plotted using Kaplan-Meier estimates (28). Gelman et al. (29) and Gaynor et al. (30) have reported that the Kaplan-Meier method produces biased estimates (overestimates, generally) of local progression and time to distant metastases. Therefore, the cumulative incidence approach was used instead to estimate values for these end points when plotting the associated graphs because it specifically adjusts for competing risks, such as dying without the recurrence of prostate cancer (31) .
Results
Tissue blocks were obtained from 261 (55%) of the 471 patients entered in RTOG 8610. After a review of hematoxylineosin-stained sections, sufficient tumor material for analysis was present for 129 patients (27% of the total patients in the trial). Pretreatment characteristics for the 456 assessable patients entered in the trial with or without p53 data are presented in Table  1 . Those patients for whom p53 data were obtained tended to have tumors with a higher Gleason score (mean score with p53 data ‫ס‬ 7.18; mean score without p53 data ‫ס‬ 6.85; P ‫ס‬ .16) and a higher clinical stage (P ‫ס‬ .28). There was also an imbalance in the number of patients with p53 data in the two treatment arms (57 treated with RT plus hormone therapy and 72 treated with RT alone). Cox regression models were used to evaluate the differences in outcome for each of the four end points between the patients with or without p53 data. The difference between the two groups achieved statistical significance for progression-free survival, with an RR of 1.34 (95% CI ‫ס‬ 1.04-1.73) associated with having p53 data (P ‫ס‬ .024). The RR associated with survival, although not significant, was 1.33 (95% CI ‫ס‬ 0.94-1.87) (P ‫ס‬ .11). For the other two end points, the associated RRs were almost equal to 1.00, which indicated no difference.
The specimen used for p53 analysis was a needle biopsy in 94 (73%) of the 129 cases and a transurethral resection in 35 (27%) of the 129 cases. There was no significant association between the type of specimen and the frequency of p53 abnormality (P>.10; chi-squared test). The central review distribution of Gleason scores for cases with a p53 determination was a score of 4 in four cases, a score of 5 in 13 cases, a score of 6 in 17 cases, a score of 7 in 52 cases, a score of 8 in 13 cases, and a score of 9 in 30 cases ( Table 2) .
Positive nuclear staining for p53 protein was detected in 71 (55%) of the 129 cases; of these, 11 cases showed only rare isolated positive cells, and an additional 37 cases had fewer than 20% positive nuclei ( Table 2 ; Fig. 1, A ). There were 23 (18%) †Karnofsky performance score (38) . ‡See (21) . §See (27) .
RT ‫ס‬ radiation therapy; hormone therapy ‫ס‬ Zoladex and flutamide. (38) . †See (21) . ‡See (27) . RT ‫ס‬ radiation therapy; hormone therapy ‫ס‬ Zoladex and flutamide.
cases with 20% or more positive nuclei (Fig. 1, B) . Three cutoff points for p53 expression were evaluated with the Cox model for each of the four end points. The first cutoff point was defined as the presence of any detectable cells; the second was defined as more than 1% but fewer than 20% positive cells; and the third was defined as 20% or more positive cells. With three of the four end points, the cutoff point of 20% or more positive cells was the most significant addition to the other three fixed covariates of clinical stage, grouped Gleason sum, and assigned treatment. It is of interest that this observation confirms the selection of 20% as a critical level of expression in other immunohistochemical studies of p53, as mentioned in ''Materials and Methods.'' For time to local progression, all three cutoff points failed to add significantly to the model. Vesalainen et al. (13) and Shurbaji et al. (19) previously reported outcome data for prostate cancer by dividing patients into groups with and without any detectable p53 immunostaining. In our series, use of a similar cutoff point would yield significant results only for progression-free survival (P ‫ס‬ .027) but not for the other three end points. The distributions of various pretreatment characteristics according to p53 expression are shown in Table 2 . The patients with abnormal expression tended to have higher Gleason scores (P ‫ס‬ .37) but a lower frequency of clinical stage T3 disease (57% for abnormal p53 versus 77% for normal p53; P ‫ס‬ .07). The last known status for all four end points according to p53 expression is summarized in Table 3 . When the outcome data were analyzed, abnormal expression of p53 was associated with a poorer result for three of the end points examined. There was no significant difference in local progression between patients with normal and abnormal p53 expression ( Fig. 2, A ; Table 4 ; P ‫ס‬ .58; RR ‫ס‬ 1.30; 95% CI ‫ס‬ 0.52-3.27). Patients with abnormal p53 expression had a significantly shortened overall survival ( Fig. 2, B ; Table 4 ; P ‫ס‬ .02; RR ‫ס‬ 2.34; 95% CI ‫ס‬ 1.21-4.51), an increased incidence of distant metastases ( Fig. 2 , C; Table 4 ; P ‫ס‬ .04; RR ‫ס‬ 2.15; 95% CI ‫ס‬ 1.08-4.27), and a reduced progression-free survival (Fig. 2, D ; Table 4 ; P ‫ס‬ .003; RR ‫ס‬ 2.45; 95% CI ‫ס‬ 1.41-4.26). The strong association between abnormal p53 expression and time to distant metastases likely explains both the reduction in progression-free and overall survival. It is not possible to be certain whether the lack of association with local progression indicates a biologic effect or reflects the development of other failures before local progression could occur. The latter would be expected if the role of apoptosis as a mechanism of cell death induced by hormone therapy and RT are important in vivo.
Analyses with Cox regression models were carried out for the four end points to see if p53 expression status was a prognostic factor independent of clinical T stage, Gleason score, and assigned treatment. Except for local progression, p53 status was found to be a significant independent prognostic indicator for time to distant metastases, progression-free survival, and overall survival. Results from the multivariate models are summarized in Table 4 .
Next, a possible interaction with treatment was considered because RTOG 8610 showed an advantage for the RT plus hormone therapy arm in two of the end points (i.e., local control and progression-free survival). A statistically significant interaction with treatment for time to distant metastases was found, with an RR of 5.91 (95% CI ‫ס‬ 1.47-23.75) (P ‫ס‬ .01). For the patients *RR ‫ס‬ relative risk ratio and associated 95% confidence interval (in parentheses). †Significance level with p53 added to the model. ‡RT ‫ס‬ radiation therapy; hormone therapy ‫ס‬ Zoladex and flutamide. §See (21) . See (27). assigned to the RT plus hormone-therapy arm, abnormal p53 staining was a powerful prognostic indicator as seen in Fig. 3 , A (P ‫ס‬ .001), with those patients with abnormal p53 having a much higher frequency of distant metastases. For the patients assigned to the RT-only arm, there was no difference in the time to distant metastases found between the two p53 groups, as seen in Fig. 3 , B (P ‫ס‬ .91). There was no statistically significant interaction found for the other three end points, although there is a striking difference in both progression-free and overall survival observed for the hormone therapy-treated patients but not for the RT-only patients. An example of this phenomenon for overall survival is shown in Fig. 4, A 
Discussion
p53 protein expression has been studied by several groups in a variety of specimen types (primary tumors and metastases) from patients with prostate cancer at all stages. These studies have revealed a fairly consistent relationship between abnormal p53 expression and high tumor grade (4, 5, (9) (10) (11) 19 ) and advanced stage (5, 6, 9, 17) . We found that patients with abnormal p53 expression had an increased frequency of high tumor grade (for Gleason scores 8 and 9, 43% of patients had abnormal p53 versus 31% of patients with normal p53; P ‫ס‬ .37) but not of clinical stage T3 disease (57% of patients had abnormal p53 versus 77% of patients with normal p53; P ‫ס‬ .56). The latter finding is not unexpected, given the lack of association between clinical stage and pathologic stage and the observation that clinical stage was not an independent prognostic indicator in this series of patients.
Few studies have assessed the prognostic value of p53 protein expression in prostate cancer. Visakorpi et al. (4) studied 137 patients treated with hormone therapy alone (n ‫ס‬ 97) or with either radical prostatectomy or radical RT (n ‫ס‬ 15); treatment was not indicated for the remaining 25 patients. Visakorpi et al. defined abnormal p53 expression as 20% or more positive cells (the same as in our study) and found significant relationships between p53 expression and both progression-free survival and overall survival. The patients with abnormal p53 expression had the poorer outcome. Shurbaji et al. (19) studied 109 patients with stage A-D1 disease treated with RT (n ‫ס‬ 39), radical prostatectomy (n ‫ס‬ 31), hormone therapy (n ‫ס‬ 14), and expectantly (n ‫ס‬ 25). Tumors with any detectable nuclear staining were considered abnormal for p53. Shurbaji et al. found p53 to be a significant prognostic indicator that was independent only for patients with tumors having Gleason scores of 7 or lower. In contrast, Vesalainen et al. (13) evaluated p53 expression in 139 patients with T1-2M0 tumors; treatment included radical prostatectomy (n ‫ס‬ 4), RT (n ‫ס‬ 2), estrogen therapy (n ‫ס‬ 2), orchiectomy (n ‫ס‬ 30), transurethral resection (n ‫ס‬ 13), and expectant management (n ‫ס‬ 79). Positive p53 staining, defined as the presence of any positive cells, was not associated with survival. These three studies all included heterogeneous patient populations with considerable variation in treatment. None of the analyses assessed possible treatment interactions with the p53 results. The findings of our study indicate a need to evaluate interactions between treatment type and the tumor marker assessed as a possible prognostic factor in future studies. It may be that p53 expression will prove to be an independent prognostic marker in patients with prostate cancer treated with RT and/or hormone therapy but not surgery alone, which does not depend on an apoptotic mechanism.
We found p53 status to be a significant prognostic indicator for overall survival, progression-free survival, and time to distant metastases for patients with locally advanced prostate cancer treated primarily by RT. For these three end points, this result was independent of clinical stage and Gleason score. For time to distant metastases, in addition to p53 being a significant prognostic indicator, a strong interaction with treatment was detected. For those patients treated with androgen ablation therapy and RT, p53 status had a highly significant relationship with time to distant metastases; in contrast, this relationship was not detected in the RT-only arm. The interaction translated into a significant survival advantage for patients without abnormal p53 expression. Although these data raise the possibility that, for those patients with abnormal p53 expression, the addition of neoadjuvant total androgen blockade prior to and during RT had a negative impact on outcome, several limitations in the data must be considered. This observation is based on a very small number of patients with abnormal p53 expression in each treatment arm (12 [17%] of 72 patients treated with RT alone and 11 [19%] of 57 patients treated with RT plus hormone therapy). Additionally, the patients with p53 determinations represented a subset of the overall study population, which has clearly demonstrated an advantage for hormone therapy (22) . The subset of patients with p53 data was shown to be nonrepresentative of the overall study population; it had a higher frequency of cases with poor prognostic factors (high Gleason score) and was associated with significantly poorer progression-free survival (P ‫ס‬ .024) and lower overall survival (P ‫ס‬ .11).
Other recent reports have indicated that p53 expression status may affect response to specific treatments. Bergh et al. (32) evaluated 316 consecutive patients with breast cancer for the presence of p53 mutations. In lymph node-positive patients, those with p53 mutations showed a significantly lower response to adjuvant therapy (axillary RT and tamoxifen) than those without a p53 mutation (31) . In a study of 52 patients with stage III non-small-cell lung cancer, Rusch et al. (33) evaluated p53 status by immunohistochemistry and reported that aberrant p53 expression was associated with a reduced pathologic response to cisplatin-based chemotherapy. To our knowledge, our study provides the first demonstration of the importance of including treatment information in the evaluation of p53 data in prostate cancer.
Tumors with abnormal p53 function may be protected from undergoing apoptosis, the believed mechanism of action of androgen-ablation therapy (1, 2) . Studies (34, 35) of the bcl-2 protooncogene in prostate cancer have demonstrated an association between bcl-2 overexpression and androgen independence, supporting an important role for apoptosis in hormone therapy for prostate cancer. It is interesting to speculate that the predictive value of p53 staining for those patients treated with the combination of androgen ablation and RT is a reflection of the blocking of this mechanism. Prendergast et al. (36) evaluated 18 samples of locally recurrent prostate cancer (following RT) for p53 alterations by immunohistochemistry, single-stranded conformation polymorphism (SSCP) analysis, and DNA sequencing. Immunohistochemical positivity was detected in 13 (72%) of the 18 tumors, a substantially higher frequency than expected for untreated tumors of similar stage and grade; mutations were detected in three of the five studied by SSCP and DNA sequencing (36) . Heterogeneity is well recognized in prostate cancers, and tumors with abnormal p53 expression also contain large numbers (usually a majority) of cells with normal expression (18, 37) . It may be that the subset of cells with abnormal p53 function (related to mutation or other mechanisms) is resistant to RT (and/or hormone therapy) and that these cells are responsible for treatment failure.
The observations in our study require further exploration. If the results can be confirmed, a role for p53 determination in therapy selection for individual patients with locally advanced prostate cancer could be prospectively assessed as part of a phase III clinical trial. In addition, the powerful prognostic value of p53 status, if confirmed, would make it a critical stratification variable for randomization in subsequent clinical trials and their analyses.
